Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy

Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy: Quantitative Analysis and Prognostic Implication

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03325036

Enrollment

Registered

2017-10-30

Start date

2017-07-01

Completion date

2024-12-30

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancers Patients

Brief summary

The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.

Interventions

DIAGNOSTIC_TESTSerum levels of immunologic profiles

Serum levels of immunologic profiles before and after chemoradiotherapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with head and neck cancer receiving curative radiotherapy in NTUH radiation therapy department.

Exclusion criteria

* Patients with head and neck cancer NOT receiving curative radiotherapy in NTUH radiation therapy department.

Design outcomes

Primary

Measure	Time frame	Description
Disease progression	Three years	Tumor local recurrence or distant metastasis

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026